Columbus Circle Investors raised its stake in Aerie Pharmaceuticals (NASDAQ:AERI) by 6.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 631,047 shares of the company’s stock after purchasing an additional 37,961 shares during the period. Columbus Circle Investors owned about 1.60% of Aerie Pharmaceuticals worth $34,234,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its holdings in shares of Aerie Pharmaceuticals by 11.5% in the 4th quarter. Bank of New York Mellon Corp now owns 613,305 shares of the company’s stock valued at $36,645,000 after acquiring an additional 63,030 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Aerie Pharmaceuticals by 4.2% in the 4th quarter. Geode Capital Management LLC now owns 322,090 shares of the company’s stock valued at $19,244,000 after acquiring an additional 12,859 shares during the last quarter. Neuberger Berman Group LLC increased its holdings in shares of Aerie Pharmaceuticals by 22.6% in the 1st quarter. Neuberger Berman Group LLC now owns 320,500 shares of the company’s stock valued at $17,387,000 after acquiring an additional 59,000 shares during the last quarter. Senzar Asset Management LLC increased its holdings in shares of Aerie Pharmaceuticals by 20.4% in the 4th quarter. Senzar Asset Management LLC now owns 278,400 shares of the company’s stock valued at $16,635,000 after acquiring an additional 47,200 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its holdings in shares of Aerie Pharmaceuticals by 14.4% in the 4th quarter. Rice Hall James & Associates LLC now owns 269,161 shares of the company’s stock valued at $16,082,000 after acquiring an additional 33,927 shares during the last quarter. 97.57% of the stock is currently owned by institutional investors.

A number of research analysts recently issued reports on AERI shares. Zacks Investment Research upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, January 22nd. BidaskClub raised Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 23rd. Canaccord Genuity raised their price target on Aerie Pharmaceuticals from $73.00 to $86.00 and gave the company a “buy” rating in a report on Thursday, January 25th. Seaport Global Securities began coverage on Aerie Pharmaceuticals in a report on Friday, January 26th. They issued a “buy” rating and a $78.00 price target for the company. Finally, Mizuho reissued a “buy” rating and issued a $87.00 price target on shares of Aerie Pharmaceuticals in a report on Monday, January 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company. Aerie Pharmaceuticals presently has an average rating of “Buy” and an average price target of $77.92.

AERI opened at $51.15 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 13.53 and a current ratio of 13.57. Aerie Pharmaceuticals has a 12 month low of $50.38 and a 12 month high of $51.40.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, May 8th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.04. analysts predict that Aerie Pharmaceuticals will post -3.75 EPS for the current fiscal year.

Aerie Pharmaceuticals Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.